
KCAS Bio will be participating in Nordic Life Science Days (NLSDays) 2025, taking place October 13-14 in Gothenburg, Sweden. The conference focuses on early-stage drug development, partnerships, and innovation within the life sciences sector. Hosted by SwedenBIO, NLSDays brings together top scientists and business developers from across Europe to explore…

KCAS Bio will be participating in the Immunogenicity & Bioassay Summit 2025, taking place October 7-10 in Alexandria, VA. This annual summit, hosted by the Cambridge Healthtech Institute, brings together leaders in immunogenicity assessment, bioassay development, and translational science to explore emerging strategies in drug development. With focused tracks on…

In the ever-evolving landscape of drug development, biomarkers have emerged as critical tools for the mechanism of action, early proof of mechanism, safety, predictive, efficacy, and monitoring treatment response. As the field advances, two major classes of biomarkers have come to the forefront: soluble biomarkers and cellular biomarkers. While…

Join KCAS Bio at Applied Pharmaceutical Analysis (APA) 2025, taking place October 6-8 in Cambridge, Massachusetts. This scientific meeting, hosted by The Boston Society features three days of expert-led workshops on Regulated Bioanalysis, Discovery Bioanalysis, and Mechanistic ADME. The Mechanistic ADME track explores innovative topics such as PROTACs, molecular…

In the process of drug discovery, an IC₅₀ assay serves as a pivotal component in the development of cutting-edge therapeutics. An effective assay can quantify the potency of compounds, enable side-by-side comparisons with competing compounds, and track how a compound performs over time. Quantifying compound inhibition also assists with pre-clinical…

Join KCAS Bio at the 2025 Festival of Biologics, taking place from September 30 to October 2 in Basel, Switzerland. This festival, hosted by Terrapinn, brings together global stakeholders across pharma, biotech, academia, regulation, and investment to explore the discovery, development, manufacturing and commercialization of biologic therapies. During presentations, panels,…

KCAS Bio will be attending the International Clinical Cytometry Meeting (ICCS) 2025 on September 26-30 in Philadelphia, PA. This annual meeting, hosted by International Clinical Cytometry Society (ICCS), brings together leaders and scientists to advance the understanding and application of technologies and methodologies in patient sample analysis. Through presentations and…

KCAS Bio will be attending the EUROTOX Congress 2025, scheduled for September 14-17 in Athens, Greece. Organized by the Federation of European Toxicologists and European Societies of Toxicology, this event will bring together leading experts and emerging scientists to explore practical approaches to sustainable health and well-being. The gathering will…

Join KCAS Bio at the 26th International Reid Bioanalytical Forum, taking place from September 8-11, 2025, in Cambourne, UK. This event, hosted by Neil Spooner and Tim Sangster, will bring together professionals and academics to exchange perspectives on current practices and challenges in bioanalysis. Featuring presentations and discussions from organizations…

In this episode of “The Weekly Bioanalysis” podcast, our hosts, Dominic Warrino and John Perkins, sit down with two key leaders shaping the company’s future — Maria Nelson, Chief Financial Officer, and Julie Deane, Chief People Officer — to discuss KCAS Bio’s strategy for balancing rapid growth with an exceptional…

In episode 21 of “The Conversational Flow” podcast, our hosts, Adam and Brian, explore the transformative power of gene therapy, starting things off by highlighting a compelling case involving CRISPR with milestones that once seemed impossible. They dive into the science behind CRISPR’s precise gene-editing capabilities and its potential for…

PCR-based assays are increasingly utilized for bioanalysis to support the development of a wide variety of therapeutics. While the largest driver for this growth has been the expanding pipeline of cell, gene, and RNA therapies, PCR-based assays are also seeing increased use in biomarker detection across all therapeutic modalities. These…